Stephen H Tsang, MD

Our Providers

Academic Appointments

  • Laszlo T. Bito Professor of Ophthalmology, and Pathology and Cell Biology

Current Administrative Positions

  • Course co-director, BMENE6510 Stem Cells, Genome Engineering and Regenerative Medicine
Stephen H Tsang, MD

Stephen H. Tsang, M.D, Ph.D. is an acclaimed clinical geneticist in the care of individuals with retinal degenerations, and is known worldwide for his pivotal research in reprogramming the metabolome as a therapeutic avenue. His team successfully treated preclinical models of Pde6a, Pde6b, Mfrp, Rho, Cngb1 and autosomal recessive bestrophin retinopathies.

His contributions were recognized by the 2005 Bernard Becker-Association of University Professors in Ophthalmology-Research to Prevent Blindness Award. He is an elected member of several honorary societies including the American Society for Clinical Investigation, Alcon Research Institute and American Ophthalmological Society. He is consistently named to various NIH study sections (DPVS standing member 2014-8) and serves on the Scientific Advisory Panel of Research to Prevent Blindness. Dr. Tsang received 2008 resident teaching award and was the Columbia ophthalmology basic science course director (2006-2018).

Dr. Tsang has been a pioneer in genome surgery in stem cells. Most recently, he has been invited to lecture at CRISPR genome surgery workshop during the annual Association for Research in Vision & Ophthalmology (ARVO) 2015, 16, 18, 19 & 20 Annual Meetings; and as a Moderator for Gene Editing/Rewriting the Genome: Moving from Association to Biology and Therapeutics session during the 65th American Society of Human Genetics (ASHG) Annual Meeting, and a lecturer at 2015 & 2016 CRISPR Revolution conference and 2020 "Progress toward Meaningful Disease Modification in Proteinopathies and Neurodegenerative Disorders" at Cold Spring Harbor Laboratory. He delivered a keynote address for a Gordon Research Conference on Feb 16th, 2020. He serves as a consultant for Cellular Tissue and Gene Therapies Advisory Committee (CTGTAC) at the Center for Biologics Evaluation and Research (CBER), FDA {2020-4 and 2011-9}.

In his New York State supported stem cell program (N09G-302), Dr Tsang is examining embryonic stem (ES) cells to model and replace diseased human retinal cells. He is one of a handful of clinicians who can direct the full spectrum of bench-to-bedside research. PI’s research on cGMP-phosphodiesterase (PDE6) is a case in point. PDE6 defects lead to blindness in 72,000 people worldwide. PI generated the world’s first gene-targeted model of retinitis pigmentosa (a PDE6 mutant), and then used these mice to dissect the underlying pathophysiology. These studies led to novel and fundamental discoveries on PDE6 regulation of G-protein-coupled-receptor signaling and, eventually, preclinical testing in the same mice; of the different therapies tested, viral-gene therapy is slated for clinical trials. Many of his publications are in widely-read general interest journals such as Science, NEJM, Lancet, Cell Stem Cell, Nature Genetics, and Journal of Clinical Investigation, which attests to the broad impact that his work has had.

Dr. Tsang graduated from Johns Hopkins University, where he began his medical genetics training under the tutelage of Professor Victor A. McKusick. He received his M.D.-Ph.D. degrees from the NIH-National Institute of General Medical Sciences Medical Scientist Training Program (MSTP) at Columbia University. Dr. Tsang then completed his residency at Jules Stein Eye Institute/UCLA, followed by studies with Professors Alan C. Bird and Graham E. Holder on improving the care of individuals with macular degenerations.

As a result of his groundbreaking metabolome reprogramming research, Dr. Tsang has earned a reputation as one of the world's foremost authority in therapeutics of neurodegenerative disoders.

Dr Tsang's genome engineering laboratory is engaged in tackling neurodegenerative disorders by pursuing investigations in three areas, two of which include patient-specific mouse models: probing the role of phosphodiesterase (PDE) signaling in neurodegeneration, developing stem cell-based therapies for photoreceptor degeneration, and correlating the genotypes of various human retinal degenerations with the phenotypes revealed in live metabolic imaging (autofluorescence). We are also currently focused on genome engineering/CRISRP approaches to reprogamming metabolome in photoreceptor to promote cell survival, which may be broadly applicable to retinal degenerative diseases, regardless of the mutation. While light-adapted normal photoreceptors have a highly anabolic and aerobic (high lactate) metabolism similar to the Warburg effect observed in stem cells, dark-adapted photoreceptors have catabolism (low lactate), high-ATP metabolism similar to neurons. To translate this anabolic therapy to humans (who would rightly reject being maintained in darkness), our laboratory is developing “genetic sunglasses” to promote a constant dark-adapted metabolic state in photoreceptor neurons while maintaining a normal light-dark circadian environment.

Board Certifications

  • Ophthalmology

Areas of Expertise

  • Adult Genetics
  • Clinical Genetics
  • Clinical Molecular Genetics
  • Diabetic Retinopathy
  • Electrophysiology
  • Eye Genetics
  • Genetic Disorder
  • Genetic Disorders
  • Genetic Testing
  • Hereditary Retinal Degeneration
  • Macular Degeneration
  • Marfan's Syndrome
  • Molecular Biology
  • Molecular Medicine
  • Pediatric Genetics
  • Precision Medicine
  • Retina Degeneration
  • Retina Disorder
  • Retinal Bleeding
  • Retinal Disease
  • Retinal Disorders
  • Retinal Vascular Disorders
  • Retinitis pigmentosa
  • Retinopathy
  • Skin Pigmentation Disorder
  • Stem Cell Transplantation
  • Vitreoretinal Disorder

Education and Training

  • Columbia University College of Physicians and Surgeons
  • Internship: New York Hospital Queens
  • Residency: UCLA - Jules Stein Eye Institute
  • Fellowship: Moorfields Eye Hospital, London

Locations

  • CUIMC/Edward S. Harkness Eye Institute

    635 West 165th Street
    New York, NY 10032
    For new and current patient appointments, call:
    (212) 305-9535
    Fax:
    (212) 342-5293
  • CUIMC/Edward S. Harkness Eye Institute Research Annex

    160 Fort Washington Ave
    5th Floor, Room 509B
    New York, NY 10032
    Phone:
    (212) 342-1189
    Fax:
    (212) 305-4987
    Email:
    sht2@cumc.columbia.edu

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • AETNA [Aetna Signature Administrators, EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Student Health]
  • AgeWell [Medicare Managed Care, Special Needs]
  • CIGNA [EPO, Great West (National), HMO, POS, PPO]
  • Elderplan [Medicare Managed Care]
  • Emblem/GHI [Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross/Blue Shield [EPO, HMO, Medicare Managed Care, PPO]
  • Local 1199 [Local 1199]
  • MagnaCare (National) [MagnaCare]
  • Medicare [Railroad, Traditional Medicare]
  • Multiplan [Multiplan]
  • MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
  • Oxford Health Plans [Freedom, Liberty]
  • Quality Health Management [Quality Health Management]
  • RiverSpring [Special Needs]
  • United Health Care [Columbia University Employee Plan, Compass (Exchange), Empire Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]

This provider accepts new patients

Appointment Phone Number: (212) 305-9535

Lab Locations

  • CUIMC/Edward S. Harkness Eye Institute

    635 West 165th Street
    New York, NY 10032
    Fax:
    (212) 342-5293
  • CUIMC/Edward S. Harkness Eye Institute Research Annex

    160 Fort Washington Ave
    5th Floor, Room 509B
    New York, NY 10032
    Phone:
    (212) 342-1189
    Fax:
    (212) 305-4987
    Email:
    sht2@cumc.columbia.edu

Honors and Awards

  • Named Lectureships
  • 2006 Dr. Isaac Bekhor Lecturer, Doheny Eye Institute at University of Southern California (9/29)
  • 2013 Dr. Paul Stringer Memorial Lectureship, McMaster University
  • 2013 Dr. Bradley Straastma Lecturer, Resident Graduation, UCLA
  • 2015 Dr. Joginder Nath Lecturer, West Virginia U. School of Medicine
  • 2016 Lecturer, World Science Festival, CRISPR Technologies
  • 1988 – 1989 Alpha Epsilon Delta, National Premedical Honor Society, Maryland Alpha (Historian)
  • 1988 – 1989 Dean’s List, The Johns Hopkins University
  • 1989 Graduate with Departmental Honor
  • 1989 Recipient of Student Activities Award, The Johns Hopkins University
  • 1989 – 1997 NIH-National Institute of General Medical Sciences Medical Scientist Training Program: MSTP fellowship PHS Grant #T32GM073667-14
  • 1995 ARVO/National Eye Institute Travel Fellowship Grant for the 1995 ARVO meeting
  • 1996 Dean’s Award for Excellence in Research, Graduate Sch of Arts & Sciences, Columbia U. Dr. Alfred Steiner Award for Best Medical Student Research, Columbia U.
  • 1997 Best Overall Presentation at Eastern Student Research Forum sponsored by American Medical Association and the University of Miami
  • 1997 Travel Grant, European Students’ Conference at the Charité in Berlin
  • 1998 Edith McKane Award in Ophthalmology, College of Physicians and Surgeons, Columbia U.
  • 1998 John Lattimer Award in Urology, College of Physicians and Surgeons, Columbia U.
  • 2000 Jules Stein Eye Institute Research Award
  • 2000 RPB-Association of University Professors in Ophthalmology (AUPO) Resident Award
  • 2001 – present Fight for Sight/Grant-In-Aid Review Panel Member
  • 2003 Burroughs-Wellcome Fund Career Award in Biomedical Sciences
  • 2003 RPB Association of University Professors in Ophthalmology Resident Award
  • 2003 Nesburn Resident Award
  • 2004 Dennis W. Jahnigen Award, American Geriatrics Society
  • 2005 Becker-AUPO-RPB Award
  • 2006 ARVO/Alcon Early Career Clinician Scientist Award
  • 2007 Charles E. Culpeper Award
  • 2008 Teacher Recognition Award, Columbia U.
  • 2008 – 2009 Listed as one of “America’s Top Ophthalmologists” by Consumers’ Research Council of America http://consumersresearchcncl.org/Healthcare/Ophthalmologists/top_ophth.html
  • 2009 Patients' Choice Award for 2008
  • 2009 Elected to Macular Society
  • 2010 Keynote Speaker, GTCbio 2nd Annual Ocular Disease & Drug Discovery conferen. May 28, 2010
  • 2012 Invited Lecturer, University of Geneva
  • 2013, 14 Elected by his peers for inclusion in Best Doctors in America®
  • 2013 ARVO Foundation Carl Camras Award
  • 2014 Foundation Fighting Blindness Visionary Award Recipient and “Banking on a Cure” Honoree
  • 2015 ARVO 2015 Annual Meeting Gene Editing Symposium Invited Lecturer in Denver, Colorado
  • 2015 Elected to American Ophthalmological Society
  • 2015 Invited Lecturer,Deutsche Ophthalmologische Gesellschaft DOG
  • 2015 Plenary lecture, Rensselaer Center for Stem Cell Research (RCSCR) - Symposium
  • 2015 Chair, Gene Editing/Rewriting the Genome Symposium American Society of Human Genetics Annual Meeting
  • 2016 Elected to American Society for Clinical Investigation
  • 2018 Young Investigator Award, Macular Society

Research Interests

  • Gene therapy
  • Genome Surgery
  • Neural Degeneration and Repair
  • Sensory Physiology
  • Stem Cell Biology

NIH Grants

  • THERAPEUTIC GENE EDITING AND MULTIMODAL IMAGING IN JUVENILE MACULAR DEGENERATION (Federal Gov)

    Jun 1 2020 - May 31 2025

    INTEGRATED ANALYSIS OF GENETIC AND CLINICAL DATA FOR RATIONAL CLINICAL TRIALS OF STARGARDT DISEASE (Private)

    Dec 1 2018 - Nov 30 2023

    GENE SILENCING AND GENE EDITING IN PHOTOTRANSDUCTION (Federal Gov)

    Jul 1 2019 - Jun 30 2023

    DEFINING BARRIERS TO GENE THERAPY (Federal Gov)

    May 1 2018 - Apr 30 2023

    TRANSLATIONAL GENE THERAPY FOR CNGB1 RETINITIS PIGMENTOSA (Federal Gov)

    Apr 1 2018 - Jan 31 2023

    CRISPR THERAPEUTIC STRATEGIES FOR THE AMELIORATION OF CRB1 RETINAL DYSTROPHIES (Private)

    Jan 1 2020 - Dec 31 2022

    QUANTITATIVE FUNDUS AUTOFLUORESCENCE IN RETINAL DISORDERS (Federal Gov)

    Mar 1 2019 - Dec 31 2022

    THEDEVELOPMENT OF PATIENT-SPECIFIC RETINAL CELLS FROM INDUCED PLURIPOTENT STEM CELL AS A MODEL FOR THE MOLECULAR, CELLULAR, AND ELECTROPHYSIOLOGIC CHARACTERIZATION (P&S Industry Clinical Trial)

    Apr 25 2017 - Apr 25 2022

    NATURAL HISTORY OF INDIVIDUALS WITH RETINAL DEGENERATION DUE TO MUTATIONS IN THE CHM GENE (P&S Industry Clinical Trial)

    Mar 10 2017 - Mar 10 2022

    ASINGLE-MASKED, RANDOMISED, CONTROLLED, PARALLEL GROUP, PHASE 3 CLINICAL TRIAL OF RETINAL GENE THERAPY FOR CHOROIDEREMIA USING AN ADENO-ASSOCIATED VIRAL VECTOR (AAV2) ENCODING RAB ESCORT PROTEIN 1 (REP1) (P&S Industry Clinical Trial)

    Feb 14 2017 - Feb 14 2022

    CRISPR SINGLE-NUCLEOTIDE POLYMORPHISM (SNP) EDITING FOR AUTOSOMAL DOMINANT DISORDERS (Private)

    Sep 1 2018 - Aug 31 2021

    COMPARATIVEEFFECTIVENESS OF CRISPRN, CRISPRD, AND CRISPRI IN PATIENT-SPECIFIC STEM CELLS (NY State Gov)

    Aug 1 2018 - Jul 31 2021

    PRECISION GENOME SURGERY IN AUTOLOGOUS STEM CELL TRANSPLANT (Federal Gov)

    Jul 1 2019 - Jun 30 2021

    DISEASE MECHANISMS UNDERLYING CRB1 LEBERS CONGENITAL AMAUROSIS USING CRB1 LCA PATIENT-DERIVED RETINAL ORGANOIDS (Private)

    Jul 1 2020 - Jun 30 2021

    GENETIC AND IMMUNOLOGIC ETIOLOGY OF CHRONIC RECURRENT MULTIFOCAL OSTEOMYLITIS (CRMO) (Federal Gov)

    Sep 1 2016 - Aug 31 2020

    GENETIC AND IMMUNOLOGIC ETIOLOGY OF CHRONIC RECURRENT MULTIFOCAL OSTEOMYLITIS (CRMO) (Federal Gov)

    Sep 1 2016 - Aug 31 2020

    GENETIC AND IMMUNOLOGIC ETIOLOGY OF CHRONIC RECURRENT MULTIFOCAL OSTEOMYLITIS (CRMO) (Federal Gov)

    Sep 1 2016 - Aug 31 2020

    THE JACKSON LABORATORY CENTER FOR PRECISION GENETICS: FROM NEW MODELS TO NOEL THERAPEUTICS (Federal Gov)

    Aug 15 2015 - Jun 30 2020

    MECHANISTIC STUDIES ON REGENERATIVE MEDICINE APPROACHES TO CHILDHOOD BLINDNESS (Federal Gov)

    Apr 1 2016 - Mar 1 2020

    MECHANISTIC STUDIES ON REGENERATIVE MEDICINE APPROACHES TO CHILDHOOD BLINDNESS (Federal Gov)

    Apr 1 2016 - Mar 1 2020

    MECHANISTIC STUDIES ON REGENERATIVE MEDICINE APPROACHES TO CHILDHOOD BLINDNESS (Federal Gov)

    Apr 1 2016 - Mar 1 2020

    CHROMOSOME-SPECIFIC CHOP-STICK THERAPY FOR BEST VITELLIFORM MACULAR DYSTROPHY & CHOPSTICK THERAPY FOR AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA (ADRP) (Private)

    Apr 16 2018 - Aug 15 2019

    GENE SILENCING AND GENE EDITING IN PHOTOTRANSDUCTION (Federal Gov)

    Sep 1 2015 - Jun 30 2019

    GENE SILENCING AND GENE EDITING IN PHOTOTRANSDUCTION (Federal Gov)

    Sep 1 2015 - Jun 30 2019

    OPTIMIZING PROGNOSTICATION FOR BESTROPHIN RETINAL DYSTROPHY USING MULTI-MODAL IMAGING (Private)

    May 18 2018 - May 17 2019

    RPB MEDICAL STUDENT FELLOWSHIP (Private)

    Jan 1 2018 - Dec 31 2018

    TA-NMT-0116-0692-COLU (Private)

    Jan 1 2016 - Dec 31 2018

    GENOME ENGINEERING OF AMD RISK ALLELES IN PATIENT-SPECIFIC STEM CELLS (Private)

    Dec 31 2016 - Dec 30 2018

    2013 RPB PHYSICIAN-SCIENTIST AWARD (Private)

    Jul 1 2013 - Jun 30 2018

    CHARACTERIZATIONS AND TREATMENT OF A MOUSE MODEL OF BUTTERFLY SHAPED PATTERNED DYSTROPHY (Private)

    Jun 30 2015 - Jun 29 2018

    DEFINING BARRIERS TO GENE THERAPY (Federal Gov)

    Apr 1 2007 - Apr 30 2018

    DEFINING BARRIERS TO GENE THERAPY (Federal Gov)

    Apr 1 2007 - Apr 30 2018

    DEFINING BARRIERS TO GENE THERAPY (Federal Gov)

    Apr 1 2007 - Apr 30 2018

    RPB MEDICAL STUDENT FELLOWSHIP (Private)

    Jul 1 2016 - Jun 30 2017

    RPB MEDICAL STUDENT FELLOWSHIP (Private)

    Jul 1 2016 - Jun 30 2017

    COMPARATIVE EFFECTIVENESS OF EMBRYONIC AND INDUCED PLURIPOTENT STEM CELL-BASED THERAPIES (NY State Gov)

    Jun 1 2014 - May 31 2017

    EVALUATING GWAS AMD CANDIDATE LOCI BY GENE EDITING IN HUMAN IPS CELLS (Federal Gov)

    Apr 1 2016 - May 15 2017

    EVALUATING GWAS AMD CANDIDATE LOCI BY GENE EDITING IN HUMAN IPS CELLS (Federal Gov)

    Apr 1 2016 - Mar 31 2017

    CONSTRUCTION OF ENGINEERED PATIENT-SPECIFIC CELLULAR MODELS OF AMD (Private)

    Apr 1 2015 - May 31 2016

    BRINGING GENE SUPPLEMENTATION THERAPY FOR INHERITED PDE6A-AND DNGA3-ASSOCIATED RETINOPATHIES INTO CLINICAL PRACTICE (Private)

    Feb 1 2015 - Jan 31 2016

    2013 RPB MEDICAL STUDENT FELLOWSHIP (Private)

    Jul 1 2013 - Dec 31 2015

    GREATER NEW YORK REGINAL RESEARCH CENTER FOR THE STUDY OF RETINAL DEGENERATIVE (Private)

    Jul 1 2010 - Jun 30 2015

    NOVEL BIPARTITE VIRAL VECTORS COMBINING RNA INTERFENCES AND GENE SUPPLEMENTATION THERAPY FOR THE THE TREATMENT OF RETINITIS PIGMENTOSA (Private)

    May 1 2014 - Apr 30 2015

    SECONDSIGHT CP003001 (P&S Industry Clinical Trial)

    Aug 3 2007 - Dec 31 2014

    FUNCTIONAL ANALYSES OF EMBRYONIC STEM CELL DERIVED RETINAL C ELLS (NY State Gov)

    Sep 1 2010 - Aug 31 2014

    EVALUATION OF DISEASE PROGRESSION IN RETINITIS PIGMENTOSA (Private)

    Jun 30 2013 - Jun 29 2014

    DISEASE PROGRESSION IN PDE6-DEFICIENT RETINITIS PIGMENTOSA PATIENTS (Private)

    Jul 1 2013 - Nov 30 2013

    ABSOLUTE FUNDUS AUTOFLUORESCENCE IN RETINAL DEGENERATIONS (Federal Gov)

    Sep 1 2012 - Aug 31 2013

    GENETIC AND ENVIRONMENTAL FACTORS IN AMD (Private)

    Apr 1 2012 - Mar 31 2013

    AMNION-DERIVED MULTIPOTENT PROGENITOR (AMP) AND AMNION-DERIVED CELLULAR CYTOKINE SOLUTION (ACCS) THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY (Private)

    Nov 7 2011 - Jan 11 2013

    STEMCELLS IN PERSONALIZED, PREDICTIVE, AND TARGETED MEDICIN E FOR AMD (Private)

    Dec 1 2011 - Nov 30 2012

    PREVENTING VISUAL HANDICAP IN CHILDREN WITH TUBEROUS SCLEROS IS COMPLEX (Federal Gov)

    Aug 28 2009 - Sep 27 2012

    STEM CELL THERAPY FOR EARLY ONSET RETINAL DYSTROPHY IN AN AN IMAL MODEL (Private)

    Aug 1 2007 - Jul 31 2012

    MODELSOF STARGARDT MACULAR DEGENERATION STRATIFICATION AND PROGRESSION USING GENOTYPE, PHENOTYPE, AND STRUCTURE/FUNCTIO (Private)

    Jun 30 2011 - Jun 29 2012

    ABSOLUTE FUNDUS AUTOFLUORESCENCE IN RETINAL DEGENERATIONS (Federal Gov)

    Sep 1 2010 - Mar 13 2012

    ABSOLUTE FUNDUS AUTOFLUORESCENCE IN RETINAL DEGENERATIONS (Federal Gov)

    Sep 1 2010 - Mar 13 2012

    ALCON BASIC SCIENCE COURSE (Private)

    Jan 3 2011 - Aug 31 2011

    NEURONAL FUNCTION RECOVERY AFTER DEGENERATION (Private)

    Jul 1 2007 - Jun 30 2011

    TRANSPLANTATION OF ES CELLS RESTORES VISUAL FUNCTION IN A RE TINITIS PIGMENTOSA MOUSE MODEL (Private)

    Mar 1 2010 - Feb 28 2011

    BASIC SCIENCE COURSE IN OPHTHALMOLOGY (Private)

    Jan 2 2007 - Dec 31 2010

    BASIC SCIENCE COURSE IN OPHTHALMOLOGY (Private)

    Jan 2 2007 - Dec 31 2010

    BASIC SCIENCE COURSE-- MACULA FOUNDATION (Private)

    Dec 5 2008 - Jul 31 2010

    ALCON BASIC SCIENCE COURSE (Private)

    Feb 1 2008 - Jun 30 2010

    ALCON BASIC SCIENCE COURSE (Private)

    Feb 1 2008 - Jun 30 2010

    PET STUDY OF TRANSCORNEAL ELECTRICAL STIMULATION IN SUBJECTS WITH RETINITIS PIGMENTOSA. (Federal Gov)

    Feb 15 2009 - Jun 30 2009

Lab Projects

  • 2008–2023 NIH-R01EY018213; PI: Stephen Tsang; Direct Costs: $250,000 per year

    Defining Barriers to Gene Therapy

    2015–2023 NIH-1R01EY024698; PI: Stephen Tsang; Direct Costs: $286,665 per year

    Genome Surgery in Stem Cells

    1U01EY030580 Precision genome surgery in autologous stem cell transplant

    2016–2020 NIH 1R01EY026682; MPI; Direct Costs: $318,599 per year

    Regenerative Medicine Approaches to Childhood Blindness

    2015-2017 R21AG050437; Direct Costs: $175,821 per year

    Genome Surgery in patient specific stem cells

    NYSTEM, SDHDOH01-C32590GG-3450000; 2018-2021; PI: Stephen Tsang; Direct Costs: $300,00 per year

    Comparative Effectiveness of Embryonic and Induced Pluripotent Stem Cell-based Therapies

    Investigate the safety and efficacy of iPS-derived RPE grafts to restore vision in mouse models of both retinal damage and retinal degeneration.

    2010–2016 Foundation Fighting Blindness Center C-NY05-0705-0312; co-PI: Stephen Tsang $70,00 per year

    Electrophysiology and Imaging Module.

Lab Members

  • Richard Davis, PhD, Associate Research Scientist
  • Tharikarn Sujirakul, MD, Ion Torrent Fellow
  • Katherine J. Wert, PhD Student
  • Deniz Erol, Research Assistant
  • Susanne Koch, PhD, Postdoctoral Fellow
  • Wen-Hsuan Wu, AAV, CRISPR Research Assistant
  • Iris Yao Li, MD, Reprogramming Fellow
  • Yi-Ting Tsai, PhD student (Metabolic Biology)
  • Jin Yang, MD, SILAC Fellow
  • Chun Wei Hsu, MS, Lentiviral Research Assistant
  • Lijuan Zhang, MD, Metabolomics Research Fellow

Scientific Results

https://en.wikipedia.org/wiki/Stephen_Tsang

https://www.youtube.com/watch?v=AeReZd3k1f4&feature=em-share_video_user

Clinical Trials

2014–2019 Global Phase III Trial of Collategene (AMG0001) Critical Limb Ischemia

2014-2017 Phase III Trial of AZD9291 versus Platinum-Based Doublet Chemotherapy Non-Small Cell Lung Cancer

2014–2017 ENDEAR Phase III Trial of ISIS-SMNRx Infantile-Onset Spinal Muscular Atrophy

2014–2016 SUMIT Phase III Trial of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) Metastatic Uveal Melanoma

2014–2016 STARRS Phase II Trial of Selinexor (KPT-330) Squamous Cell Carcinoma

2014–2016 Phase II Trial of AZD9291Non-Small Cell Lung Cancer

2013–2018 Phase I/II Trial of ASP2215 Treatment-Refractory Acute myeloid Leukemia FLT3 Mutation

2013–2018 Study Title: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
2013–2018 Phase III Trial of MK-8931m Amnestic Mild Cognitive Impairment in Alzheimer’s Disease

2013–2017 APOLLO Phase III Trial of Patisiran (ALN-TTR02)TTR-mediated Amyloidosis

2013–2015 Phase II Clinical Trial of Revusiran (ALN-TTRsc) TTR-mediated Cardiac Amyloidosis

2015-2018 Phase II Clinical Trial of AAV2-REP1 Choroideremia gene therapy